Abstract
Viral hepatitis remains the leading cause of liver failure and is the primary indication for liver transplantation worldwide. Hepatitis viruses are categorized into five distinct subtypes that collectively render significant morbidity and mortality in transplanted patients. Each subtype has a distinct replication pattern, pathology, and treatment. While the primary pathology mediated by these viruses occurs within the liver, significant extrahepatic disease may be observed with particular subtypes of hepatitis and warrant special treatment modalities prior to and following transplantation. Advances in the management of hepatitis B and C have recently revolutionized the treatment paradigm from supportive care to cure. In this section, each hepatitis subtype is described separately and accompanied by diagnostic and treatment strategies with emphasis on care for the transplanted patient.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L, Hepatitis A. Epidemiology and prevention in developing countries. World J Hepatol. 2012;4(3):68–73.
Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14(1):38–58.
Trepo C, Zoulim F, Pradat P. Viral hepatitis. Curr Opin Infect Dis. 1999;12(5):481–90.
Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357(17):1685–94.
Matheny ME, Fitzhenry F, Speroff T, Green JK, Griffith ML, Vasilevskis EE, et al. Detection of infectious symptoms from VA emergency department and primary care clinical documentation. Int J Med Inform. 2012;81(3):143–56.
Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). Hepato-Gastroenterology. 2000;47(33):786–9.
Yoon EL, Yim HJ, Kim SY, Kim JH, Lee JH, Lee YS, et al. Clinical courses after administration of oral corticosteroids in patients with severely cholestatic acute hepatitis A; three cases. Korean J Hepatol. 2010;16(3):329–33.
Attili AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol. 1994;20(3):315–20.
Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc. 2006;117:227–37; discussion 37–8
Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338(5):286–90.
Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology. 2006;44(6):1589–97.
Arslan M, Wiesner RH, Poterucha JJ, Gross JB Jr, Zein NN. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl. 2000;6(2):191–5.
Eisenbach C, Longerich T, Fickenscher H, Schalasta G, Stremmel W, Encke J. Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J Clin Virol. 2006;35(1):109–12.
Park GC, Hwang S, Yu YD, Park PJ, Choi YI, Song GW, et al. Intractable recurrent hepatitis A virus infection requiring repeated liver transplantation: a case report. Transplant Proc. 2010;42(10):4658–60.
Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27(3):881–6.
Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999;94(6):1601–4.
Brundage SC, Fitzpatrick AN, Hepatitis A. Am Fam Physician. 2006;73(12):2162–8.
Martin K, Drabble A, Manlhiot C, Dipchand AI. Response to hepatitis A and B vaccination after pediatric heart transplant. Pediatr Transplant. 2012;16(7):699–703.
Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation. 2001;71(3):477–9.
Unal Ince E, Ertem M, Ileri T, Sayili A, Belgemen T, Uysal Z. Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 2010;45(1):171–5.
Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int. 2017;11(6):500–8.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.
Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9(2):191–211, v
Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95(5):755–60.
Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(5 Suppl):S28–34.
Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996;38(Suppl 2):S18–23.
LeFevre ML, U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(1):58–66.
Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771–4.
Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92(6):1844–50.
Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82.
Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005;11(7):716–32.
Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842–7.
Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10(8):968–74.
Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol. 2012;56(5):1189–97.
Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6(6):741–8.
Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528–35.
Young K, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, et al. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. J Viral Hepat. 2017;24(9):789–96.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.
Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38 Suppl 1:84–9.
Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47(6):730–7.
Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts – a systematic analysis. Clin Transpl. 2011;25(3):E243–9.
Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95(7):960–5.
Degott C, Degos F, Jungers P, Naret C, Courouce AM, Potet F, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver. 1983;3(6):377–84.
Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996;62(2):297–9.
Raheem OA, Hickey DP. Treatment of hepatitis B virus reactivation in a cadaveric renal transplant recipient with entecavir. Arab J Nephrol Transplant. 2013;6(1):41–4.
Rivolta E, De Vecchi A, Tarantino A, Castelnovo C, Berardinelli L, Ponticelli C. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients. Transplant Proc. 1987;19(1 Pt 3):2153–4.
Flagg GL, Silberman H, Takamoto SK, Berne TV. The influence of hepatitis B infection on the outcome of renal allotransplantation. Transplant Proc. 1987;19(1 Pt 3):2155–8.
Huang CC, Lai MK, Fong MT. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation. 1990;49(3):540–4.
Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257–63.
Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5(12):2913–21.
Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol. 2001;21(4):300–6.
Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol. 2011;6(6):1481–7.
Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transpl. 2002;16(2):130–6.
Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.
Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36(5):1246–52.
Ahn HJ, Kim MS, Kim YS, Kim SI, Huh KH, Ju MK, et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol. 2007;79(11):1655–63.
Park KS, Yang WS, Han DJ, Park JB, Park JS, Park SK. Long-term impact of prophylactic antiviral treatment in Hepatitis B surface antigen positive renal allograft recipients. Clin Nephrol. 2012;78(4):303–11.
Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.
Daude M, Rostaing L, Saune K, Lavayssiere L, Basse G, Esposito L, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation. 2011;91(8):916–20.
Drescher J, Wagner D, Haverich A, Flik J, Stachan-Kunstyr R, Verhagen W, et al. Nosocomial hepatitis B virus infections in cardiac transplant recipients transmitted during transvenous endomyocardial biopsy. J Hosp Infect. 1994;26(2):81–92.
Wedemeyer H, Pethig K, Manns MP, Boker KH. Hepatitis B infection in heart transplant patients. Gastroenterology. 2001;120(5):1311–3.
Potthoff A, Tillmann HL, Bara C, Deterding K, Pethig K, Meyer S, et al. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J Viral Hepat. 2006;13(11):734–41.
Wang SS, Chou NK, Ko WJ, Yu HY, Chen YS, Hsu RB, et al. Heart transplantation using donors positive for hepatitis. Transplant Proc. 2004;36(8):2371–3.
Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997;19(8):795–9.
Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant. 1995;15(1):145–8.
Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989;4(2):207–8.
Hashino S, Nozawa A, Izumiyama K, Yonezumi M, Chiba K, Kondo T, et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002;29(4):361–3.
Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12(1):84–94.
Myers RP, Swain MG, Urbanski SJ, Lee SS. Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15(9):599–603.
Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48(5):1001–26.
Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17(1):1–15.
Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17(15):1927–38.
Giudice CL, Martinengo M, Pietrasanta P, Bocciardo L, Malavasi C, Rastelli S, et al. Occult hepatitis B virus infection: a case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. Blood Transfus. 2008;6(1):46–50.
Chen GD, Gu JL, Qiu J, Chen LZ. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers. Transpl Infect Dis. 2013;15(3):300–5.
Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl. 2004;10(3):356–62.
Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2(8):479–86.
Cardell K, Akerlind B, Sallberg M, Fryden A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis. 2008;198(3):299–304.
Pin M, Compte MT, Angelet P, Gallego C, Gutierrez C, Martinez Vea A. Long-term evaluation of immune response to hepatitis B vaccine in 136 patients undergoing hemodialysis. Nefrologia. 2009;29(5):415–20.
Kramer ES, Hofmann C, Smith PG, Shiffman ML, Sterling RK. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci. 2009;54(9):2016–25.
Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429–38.
Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 8th ed. Philadelphia, PA: Elsevier; 2016. x, 836 p
Smith DB, Simmonds P, International Committee on the Taxonomy of Viruses Hepeviridae Study Group, Jameel S, Emerson SU, Harrison TJ, et al. Consensus proposals for classification of the family Hepeviridae. J Gen Virol. 2015;96(Pt 5):1191–2.
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.
Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14(1):1–21, vii
Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12(5):408–14.
Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25(7):899–904.
Williams JL, Cagle HH, Christensen CJ, Fox-Leyva LK, McMahon BJ. Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992. Transfusion. 2005;45(6):1020–6.
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8.
Gonzalez-Grande R, Jimenez-Perez M, Gonzalez Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22(4):1421–32.
Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401–12.
Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, et al. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42(1):86–92.
Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut. 1999;45(4):613–7.
Hughes RD, Wendon J, Gimson AE. Acute liver failure. Gut. 1991;32(Suppl):S86–91.
Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418–31.
Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34(4 Pt 1):809–16.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.
Giannini E, Mastracci L, Botta F, Romagnoli P, Fasoli A, Risso D, et al. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol. 2001;13(11):1355–61.
Larson AM, Taylor SL, Bauermeister D, Rosoff L Jr, Kowdley KV. Pilot study of the relationship between histologic progression and hepatic iron concentration in chronic hepatitis C. J Clin Gastroenterol. 2003;37(5):406–11.
Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75–85.
Zarski JP, Mc Hutchison J, Bronowicki JP, Sturm N, Garcia-Kennedy R, Hodaj E, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol. 2003;38(3):307–14.
Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51(4):655–66.
Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–59.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22–6.
Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.
Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344–55.
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72.
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372–80.
El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4(1):5–10.
Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006;130(3):703–14.
George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729–38.
Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127(10):875–81.
Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52(1):132–41.
Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.
Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51(6):2069–76.
Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):932–7.
Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38(3):322–7.
Gonzalez SA, Trotter JF. The rise of the opioid epidemic and hepatitis C positive organs: a new era in liver transplantation. Hepatology. 2018;67(4):1600–8.
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33.
Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Management of post transplant hepatitis C in the direct antiviral agents era. Hepatol Int. 2015;9(2):192–201.
Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol. 2011;26(Suppl 1):96–101.
Chan A, Patel K, Naggie S. Genotype 3 infection: the last stand of hepatitis C virus. Drugs. 2017;77(2):131–44.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–54.
Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol. 2014;20(32):11095–115.
Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110(1):167–77.
Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334(13):815–20.
Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5):830–6.
Watt KD, Laryea MA. Recurrent disease following liver transplantation. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff’s diseases of the liver. 11th ed. Philadelphia, PA: Wiley & Sons; 2012. p. 1152–66.
Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 2007;13(2):219–26.
Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19(4):904–9.
Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335–42.
Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52–61.
Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55(1):4–13.
Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis. 2004;19(3–4):357–81.
Pischke S, Cornberg M, Manns MP. Hepatitis associated cryoglobulinemia. Internist (Berl). 2008;49(3):297–304.
White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44.
Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42(4):631–57.
Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol. 1992;38(1):44–8.
Chan TM, Lok AS, Cheng IK. Hepatitis C in renal transplant recipients. Transplantation. 1991;52(5):810–3.
Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol. 1995;23(1):28–31.
Arenas MD, Sanchez-Paya J, Barril G, Garcia-Valdecasas J, Gorriz JL, Soriano A, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant. 2005;20(6):1164–71.
Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28(4):628–40.
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20(11–12):1271–7.
Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5(1):139–44.
Pham T. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. CANNT J. 2001;11(3):46.
Patel PR, Thompson ND, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56(2):371–8.
Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis. 1993;168(6):1343–8.
Dalekos GN, Boumba DS, Katopodis K, Zervou E, Sferopoulos G, Elisaf M, et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant. 1998;13(7):1804–6.
Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, et al. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation. 2002;74(10):1473–5.
Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2(3):563–75.
Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;(109):S1–99.
Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123(5):1494–9.
Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant. 2005;5(7):1704–12.
Delladetsima I, Psichogiou M, Sypsa V, Psimenou E, Kostakis A, Hatzakis A, et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis. 2006;47(2):309–16.
Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29(4):608–14.
Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation. 2005;79(9):1132–6.
Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. 2001;59(2):732–7.
Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation. 1995;59(12):1676–82.
Papafragkakis H, Fabrizi F, Martin P. Viral hepatitis in renal transplantation. Clin Nephrol. 2011;76(1):29–39.
Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Fuertes A, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 1995;47(1):236–40.
Ali MK, Light JA, Barhyte DY, Sasaki TM, Currier CB Jr, Grandas O, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation. 1998;66(12):1694–7.
Gupta G, Kang L, Yu JW, Limkemann AJ, Garcia V, Bandyopadhyay D, et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: analysis of United States national data. Clin Transpl. 2017;31(10)
Fagiuoli S, Minniti F, Pevere S, Farinati F, Burra P, Livi U, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant. 2001;20(7):718–24.
Cadranel JF, Di Martino V, Dorent R, Bernard B, Hoang C, Myara A, et al. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study. Transplantation. 2003;75(7):977–82.
Lake KD, Smith CI, Milfred-La Forest SK, Pritzker MR, Emery RW. Outcomes of hepatitis C positive (HCV+) heart transplant recipients. Transplant Proc. 1997;29(1–2):581–2.
Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation. 2009;88(9):1137–41.
Lee I, Localio R, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, et al. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant. 2011;30(11):1266–74.
Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2(5):443–7.
Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 1999;30(5):1293–8.
Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006;296(15):1843–50.
Trakroo S, Qureshi K. Successful treatment of chronic hepatitis C infection with direct-acting antivirals in a heart transplant recipient: a case report. Transplant Proc. 2015;47(7):2295–7.
Fong TL, Cho YW, Hou L, Hutchinson IV, Barbers RG, Herrington CS. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation. 2011;91(11):1293–6.
Carreno MC, Piedad UG, Maite L, Andres V, Francisca P, Cesar B, et al. Hepatitis C virus infection after lung transplantation: dim prognosis. J Heart Lung Transplant. 2001;20(2):224.
Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(7):745–55.
Carbone M, Lenci I, Baiocchi L. Prevention of hepatitis C recurrence after liver transplantation: an update. World J Gastrointest Pharmacol Ther. 2012;3(4):36–48.
Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol. 1994;88(2):392–4.
Silvestri F, Barillari G, Fanin R, Pipan C, Falasca E, Salmaso F, et al. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas. Haematologica. 1997;82(3):314–7.
Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007;60(12):1378–83.
Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89–94.
Levine AM, Shimodaira S, Lai MM. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa. N Engl J Med. 2003;349(21):2078–9.
Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med. 2012;51(19):2745–7.
Locasciulli A, Testa M, Valsecchi MG, Bacigalupo A, Solinas S, Tomas JF, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation. 1999;68(10):1486–91.
Lyra AC, Brunt EM, Pincus S, Di Bisceglie AM. A 32-year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant. Semin Liver Dis. 2002;22(1):103–8.
Hwang YY, Liang RH. Hepatitis C in haematological patients. Hepat Res Treat. 2010;2010:961359.
Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86(4):1614–8.
Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103(5):1618–24.
Peffault de Latour R, Asselah T, Levy V, Scieux C, Devergie A, Ribaud P, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2005;36(8):709–13.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this chapter
Cite this chapter
Merola, J., Jow, A.Z., Sigal, S.H. (2019). Hepatitis A, B, and C. In: Safdar, A. (eds) Principles and Practice of Transplant Infectious Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-9034-4_41
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9034-4_41
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-9032-0
Online ISBN: 978-1-4939-9034-4
eBook Packages: MedicineMedicine (R0)